Immunotherapy News and Research

Latest Immunotherapy News and Research

Professor Jonathan Sprent named recipient of AAI Lifetime Achievement Award

The American Association of Immunologists has selected Professor Jonathan Sprent FAA FRS, from Sydney's Garvan Institute of Medical Research, to be the 2015 recipient of the AAI Lifetime Achievement Award.

23 Jan 2015

NCCS launches human clinical trial of new cancer vaccine

The National Cancer Centre Singapore has launched a clinical trial of a new cancer vaccine administered to human patients for the first time in the world. Cancer immunotherapy (the harnessing of the body's defence system to fight the patient's cancer, has emerged as one of the most exciting medical breakthroughs in the past two years.

22 Jan 2015

New experimental study shows immunotherapy can reduce acute effects of heroin

Immunotherapy could have a place in the treatment of substance abuse in the future. A specific antibody can reduce the acute effects of heroin, according to a new experimental study at the Norwegian Institute of Public Health.

21 Jan 2015

ASCO announces cancer Advance of the Year

The American Society of Clinical Oncology for the first time announced its cancer Advance of the Year: the transformation of treatment for the most common form of adult leukemia. Until now, many patients with chronic lymphocytic leukemia (CLL) have had few effective treatment options. Four newly approved therapies, however, are poised to dramatically improve the outlook for patients with the disease.

20 Jan 2015

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%.

20 Jan 2015

Tübingen researchers develop new way of labeling T-cells

To better understand what happens during immune reactions in the body, researchers at Tübingen University have developed a new way of labeling T-cells, allowing them to track the T-cell movement in mice using non-invasive positron emission technology (PET).

19 Jan 2015

CAR T-cell therapy enters into Phase I clinical trial

Cancer fighting chimeric antigen receptor (CAR) T cells, developed in the Sentman laboratory of Dartmouth's Norris Cotton Cancer Center, are taking the next step into a Phase I clinical trial beginning early in 2015.

15 Jan 2015

Intrexon and ZIOPHARM Oncology sign exclusive licensing agreement with MD Anderson

Intrexon Corporation, a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology, today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.

14 Jan 2015

Study assesses therapeutic benefits of new oral immunotherapy for children allergic to wheat

The study carried out by researchers from the Centre for Plant Biotechnology and Genomics along with the Allergy Department of the Hospital Infantil Universitario Niño Jesús of Madrid have shown that, most of the children that received this new oral immunotherapy treatment were able to eat 100 grams of wheat bread without side effects. This result has overcome the risk of accidental ingestion by patients with this allergy. This research could be the basis for large clinical trials with more patients with the aim of assessing the therapeutic benefit of this new approach.

13 Jan 2015

TxCell announces further enhancement to development of Ovasave for IBD treatment

Paulsen Foundation to provide specialist management and scientific and development expertise that is dedicated to advanced therapies, i.e. cellular and gene therapies. This new class of highly promising biological therapies includes TxCell’s Ovasave.

5 Jan 2015

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

1 Jan 2015

FDA receives IDE application for CytoSorbents' CytoSorb cardiac surgery trial

CytoSorbents Corporation, a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced today that it has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to conduct its proposed clinical trial using CytoSorb® intra-operatively in patients undergoing complex cardiac surgery requiring the use of a heart-lung machine.

31 Dec 2014

Pivotal trial of Elios melanoma vaccine to be conducted at top U.S. cancer hospitals

Elios Therapeutics, LLC recently received FDA approval of its Investigational New Drug (IND) application and its randomized phase IIb trial planned to enroll 120 stage III and IV (resected) melanoma patients to assess the ability of a personalized vaccine to prevent recurrence.

23 Dec 2014

CytoSorbents starts trading on The Nasdaq Capital Market

CytoSorbents Corporation, a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced that it will commence trading today on The Nasdaq Capital Market under its current ticker symbol "CTSO".

23 Dec 2014

Scientists identify white blood cells that tumors use to suppress disease-fighting immune system

A study led by St. Jude Children's Research Hospital scientists has identified the population of white blood cells that tumors use to enhance growth and suppress the disease-fighting immune system.

19 Dec 2014

Inovio begins hTERT DNA immunotherapy trial in adults with breast, lung and pancreatic cancer

Inovio Pharmaceuticals, Inc. announced it has initiated a phase I trial of its hTERT DNA immunotherapy (INO-1400) alone or in combination with Inovio's IL-12 immune activator (INO-9012) in adults with breast, lung, or pancreatic cancer at high risk of relapse after surgery and other cancer treatments.

18 Dec 2014

EC grants orphan drug designation to TxCell's Col-Treg for treatment of autoimmune uveitis

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the European Commission (EC) has granted orphan drug designation to TxCell's investigational medicinal product Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of autoimmune uveitis.

18 Dec 2014

Scientists produce novel class of molecules that could help combat cancer, other diseases

Promising treatments known as biologics are on the market and under development for many serious illnesses such as cancer, but some of them come with high risks, even lethal ones. Now scientists have produced a novel class of molecules that could be as effective but without the dangerous side effects.

17 Dec 2014

OncoTherapy Network discusses latest research on prostate cancer

UBM Medica US announces that OncoTherapy Network, a leading online community to help oncologists and other clinicians gain a better understanding of the newest information available regarding the use of targeted therapies and immunotherapies, discusses some of the latest research on prostate cancer.

11 Dec 2014

PD-L1 expression tied to favourable prognosis in SCLC

Programmed death-ligand 1 is expressed by around 70% of small-cell lung cancers and is associated with favourable patient outcomes, Japanese researchers report.

10 Dec 2014

Immunotherapy News and Research

Latest Immunotherapy News and Research

Professor Jonathan Sprent named recipient of AAI Lifetime Achievement Award

NCCS launches human clinical trial of new cancer vaccine

New experimental study shows immunotherapy can reduce acute effects of heroin

ASCO announces cancer Advance of the Year

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Tübingen researchers develop new way of labeling T-cells

CAR T-cell therapy enters into Phase I clinical trial

Intrexon and ZIOPHARM Oncology sign exclusive licensing agreement with MD Anderson

Study assesses therapeutic benefits of new oral immunotherapy for children allergic to wheat

TxCell announces further enhancement to development of Ovasave for IBD treatment

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

FDA receives IDE application for CytoSorbents' CytoSorb cardiac surgery trial

Pivotal trial of Elios melanoma vaccine to be conducted at top U.S. cancer hospitals

CytoSorbents starts trading on The Nasdaq Capital Market

Scientists identify white blood cells that tumors use to suppress disease-fighting immune system

Inovio begins hTERT DNA immunotherapy trial in adults with breast, lung and pancreatic cancer

EC grants orphan drug designation to TxCell's Col-Treg for treatment of autoimmune uveitis

Scientists produce novel class of molecules that could help combat cancer, other diseases

OncoTherapy Network discusses latest research on prostate cancer

PD-L1 expression tied to favourable prognosis in SCLC

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Immunotherapy News and Research

Latest Immunotherapy News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in